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Mylk3 null C57BL/6N mice develop cardiomyopathy,
whereas Nnt null C57BL/6J mice do not
Jack L Williams1, Anju Paudyal2, Sherine Awad1, James Nicholson1, Dominika Grzesik1, Joaquin Botta1 ,
Eirini Meimaridou3, Avinaash V Maharaj1 , Michelle Stewart2, Andrew Tinker4, Roger D Cox5 , Lou A Metherell1
The C57BL/6J and C57BL/6N mice have well-documented phe-
notypic and genotypic differences, including the infamous nic-
otinamide nucleotide transhydrogenase (Nnt) null mutation in
the C57BL/6J substrain, which has been linked to cardiovascular
traits in mice and cardiomyopathy in humans. To assess whether
Nnt loss alone causes a cardiovascular phenotype, we investi-
gated the C57BL/6N, C57BL/6J mice and a C57BL/6J-BAC trans-
genic rescuing NNT expression, at 3, 12, and 18 mo. We identified a
modest dilated cardiomyopathy in the C57BL/6N mice, absent in
the two B6J substrains. Immunofluorescent staining of car-
diomyocytes revealed eccentric hypertrophy in these mice, with
defects in sarcomere organisation. RNAseq analysis identified
differential expression of a number of cardiac remodelling genes
commonly associated with cardiac disease segregating with the
phenotype. Variant calling from RNAseq data identified a myosin
light chain kinase 3 (Mylk3) mutation in C57BL/6N mice, which
abolishes MYLK3 protein expression. These results indicate the
C57BL/6J Nnt-null mice do not develop cardiomyopathy; however,
we identified a null mutation in Mylk3 as a credible cause of the
cardiomyopathy phenotype in the C57BL/6N.
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Introduction
Differences in background genetics can produce many different
baseline phenotypes in the ever-growing library of laboratory
mouse strains, and these can have profound influences on the
expression of particular trait(s) (1, 2, 3, 4, 5). In the last decade, a
body of research has begun to enumerate these differences, in-
cluding differences in metabolism, disease susceptibility, cardio-
vascular function, behaviour, and many more (6, 7, 8, 9). Particularly
well studied are the C57BL/6 substrains; the C57BL/6J (B6J), previously
themost widely used substrain, and the C57BL/6N (B6N), which the
International Mouse Phenotyping Consortium (IMPC) has chosen
as the background for their 20,000 gene knockouts (https://
www.mousephenotype.org/). Many genetic differences are
known to exist between these two closely related substrains
with perhaps the most commonly studied the nicotinamide
nucleotide transhydrogenase (Nnt) mutations in the B6J.
In 2012, NNT was identified as the causative gene in 15 families
with familial glucocorticoid deficiency, a disorder of adrenal in-
sufficiency without heart involvement (10, 11). Subsequently, a
further 19 families have been reported, with a single, highly con-
sanguineous patient developing hypertrophic CM with a homozy-
gous NNT mutation and three monoallelic variants have been
linked to left ventricular non-compaction (10). A number of pub-
lications have linked NNT expression levels to cardiovascular traits,
including remodelling differences, hypertension, and heart growth
in mice and zebra fish (12, 13, 14, 15, 16). Surprisingly, research from
the Maack Lab showed the NNT-null B6J mouse is protected from
oxidative stress and heart failure in comparison with the B6N
mouse, possibly because of a “reverse activity” of NNT in the B6N
mouse (14). Furthermore, the NNT-replete B6Nmice show increased
fibrosis in response to chronic angiotensin II treatment, along with
increased expression of cardiac remodelling genes; however, the
authors demonstrate these changes are not due to NNT status (15).
B6N mice are more susceptible to transaortic constriction than B6J
with B6N having lower survival rates and cardiac function (17). The
paucity of epidemiological evidence combined with the conflicting
data in mouse models means NNT’s contribution to cardiac phe-
notypes is uncertain.
In this study, we aimed to define the role of NNT in CM using the
B6J NNT-null mice and a rescue model in the B6J mice, restoring
NNT expression by expression of a bacterial artificial chromosome
with the full-length Nnt gene (C57BL/6J-BAC, NNT transgenic
[B6J-Nnt]) (18). We also compared both of these strains with the
closely related, NNT-replete, B6N mouse to assess whether NNT or
another strain-specific gene(s) causes differential phenotypes be-
tween substrains, as has been previously reported (13, 14, 15, 17).
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Here, we show that the B6J do not develop CM, even when aged to 18
mo, suggesting NNT loss alone does not cause CM. However, surpris-
ingly over time, the B6N develop CM that is absent in both the B6J and
B6J-Nnt. We go on to show that the CM in B6N may be due to a null
mutation inmyosin light chain kinase 3 (Mylk3), which is only present in
B6N substrains. MYLK3 phosphorylates myosin light chain 2 (MYL2),
which is itself essential for the assembly of actin fibres in the heart and
mutated in many human cases of CM (19, 20).
Results
B6N mice develop CM, whereas B6J do not
To ascertain whether the B6J substrain developed CM, male mice
from the three substrains B6N, B6J, and B6J-Nnt were analysed at 3,
12, and 18 mo of age, assessing cardiac form and function by
echocardiography 1 wk before sacrifice (Fig 1 [12 mo], Fig S1 [col-
lated], Fig S2 [3 mo], Fig S3 [18 mo], and Table S1 [collated]). This
revealed a clear strain-dependent difference in dynamic heart
structure, with dilated cardiomyopathy (DCM) in the B6N, partic-
ularly striking at 12 mo (Fig 1A and Table S1B). B6N mice had larger
left ventricular internal diameter at both diastole and systole (Fig
1B and C) and correspondingly larger left ventricular volume (Fig 1D
and E) than the B6J and B6J-Nnt. However, B6Nmice had thinner left
ventricular anterior wall and posterior wall thicknesses, indicating a
thinning or stretching of the muscle walls (Fig 1F–I). This resulted in
a lowered ejection fraction and reduced fractional shortening (Fig
1K and L). There was also a reduction in cardiac output, stroke
volume, and heart rate in the B6N (Fig 1J, M, and N). We observed no
difference in heart weight at this age (Fig 1O). These parameters
represent a remarkable difference in the cardiac phenotype of
these two closely related substrains consistent with a modest DCM
in the B6N rather than the B6J mice.
At 3 mo, some aspects of the divergent phenotype were present,
as the B6N hearts have higher left ventricular internal diameter and
left ventricular volume at both systole and diastole, as well as
thinner left ventricular posterior wall at systole than both B6J and
B6J-Nnt mice (Table S1A and Fig S2B–N). At 18 mo, the phenotype
maintains, as the B6N hearts had thinner anterior and posterior
walls as well as enlarged ventricles (Table S1C and Fig S3B–N). The
dilated B6N hearts were hypofunctional, reflected in the reduced
ejection fraction and fractional shortening (Fig S3K and L). At 18 mo,
there was far more intragroup variability (Table S1C), which may
explain the slightly higher significance values at this age compared
with 12 mo (Fig S1A–M).
Dilation of the ventricles and thinning of the walls in the B6Nmay
indicate a difference in the heart size, commonly measured by
heart weight. Although all three groups exhibited a progressive
increase in heart weight as they got older (Figs 1O, S1N, S2O, and
S3O), there was no significant difference amongst groups at any
time point. Body size, assessed by tibia length, was no different
between B6N and B6J substrains, indicating no change in the heart
weight:tibia length ratio in the B6Ns (data not shown). We saw no
difference in survival across the groups, indicating the phenotype is
nonlethal under normal conditions.
Cardiomyocytes are “stretched” in B6N hearts
Changes in cardiac function can be driven by gross structural
changes such as those we see here, and this can be reflected in, and
even driven by, changes in microscopic structure. Haematoxylin
and eosin staining did not reveal any difference in heart size, as
measured by the base–apex length (Fig 2A and B). We also observed
no increased fibrosis in B6N hearts at 18 mo, barring one individual
in the B6N group (Fig 2C and D). Interestingly, this individual was an
outlier within this group in many echocardiographic parameters,
having lower left ventricular volume and thicker muscle walls (Fig
S3B).
Volume overload, similar to that observed in the B6N group, can
stretch the ventricles and the heart responds by recruiting sar-
comeres in series with existing sarcomeres, elongating the car-
diomyocytes. This response, known as eccentric hypertrophy, is
common in endurance athletes, but can also present in instances of
cardiac dysfunction, and typically increases contractile force
according to the Frank–Starling mechanism (21). We used wheat
germ agglutinin to delineate cell membranes and allow us to
measure cardiomyocyte length and cross-sectional area (CSA) in
longitudinal and transverse sections, respectively (22) (Fig 2E and F).
We observed an increase in cardiomyocyte length in B6N hearts,
coupled with a striking reduction in CSA, suggesting the car-
diomyocytes are “stretched” in these mice (Fig 2G and H). We
hypothesised this might be due to changes in sarcomere organi-
sation, typical of eccentric hypertrophy. We used MYL2 as a marker
of the A band and alpha-actinin (ACTN1) as a marker of the Z-line in
serial sections of heart tissue to measure sarcomere length (the
distance between repeating units) and sarcomere thickness (across
the short axis of the cell) (Fig 2I and J). B6N sarcomeres are thinner;
however, there was no difference in sarcomere length (Fig 2K and L).
Furthermore, there was no difference in the total expression of a
panel of actomyosin and sarcomere markers when measured by
Western blot and densitometry (MYL2, ACTN1, and TNNT2) (Fig 2M).
These data indicate both the form and function of the hearts in
B6N mice are compromised. This may result from mutation of a key
cardiac gene or may be acquired as a consequence of other disease
states, such as hypertension, diabetes, or infection. However, we
found no differences in blood biochemistry consistent with a hy-
pertensive phenotype (Fig S4). There were no differences in plasma
ions (Fig S4A); however, there were significantly higher total cho-
lesterol, low-density lipoprotein, and high-density lipoprotein
levels at 18 mo in blood from the B6N group but not at other time
points (Fig S4B). Furthermore, other studies have shown the B6N
mice in fact have lower blood pressure than the B6J, all but
eliminating hypertension as the cause of the phenotype (23).
B6N transcriptome is enriched for cardiac remodelling genes
Finding no obvious cause for the cardiac remodelling in the bio-
chemistry or haematology, we wanted to determine whether
changes in gene expression could underpin the differences in
macro- and microstructure. To this end, we performed RNAseq on
heart tissues from five 18-mo-old male mice per group. We used a
CuffDiff TopHat pipeline to identify differentially expressed genes
between groups. We initially performed pathway analysis on all
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Figure 1. B6N mice exhibit dilated CM.
(A) Representative echocardiogram traces from three 12-mo-old mice at each genotype. (B) LVID;d, left ventricular internal diameter at the end of diastole. (C) LVID;s, left
ventricular internal diameter at the end of systole. (D) Left ventricular volume at the end of diastole. (E) Left ventricular volume at the end of systole. (F) LVAW;d, left ventricular
anterior wall thickness at the end of diastole. (G) LVAW;s, left ventricular anterior wall thickness at the end of systole. (H) LVPW;d, left ventricular posterior wall thickness at the
end of diastole. (I) LVPW;s, left ventricular posterior wall thickness at the end of systole. (J) Cardiac output = stroke volume × heart rate. (K) Ejection fraction = stroke volume/
end diastolic volume. (L) Fractional shortening = (LVID;d − LVID;s)/LVID;d. (M) Stroke volume = volume at the end of diastole − volume at the end of systole. (N) Heart rate.
(O) Heart weights of 12-mo-old mice at cull. Kruskal–Wallis, B6N n = 10, B6J n = 8, B6J-Nnt n = 11, mean ± SD, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
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Figure 2. Differences in microstructure of the heart amongst the three strains.
(A) Representative images of 18-mo heart tissues stained with haematoxylin and eosin. Scale bar = 4,000 μm. (B) Base–apex measurements from H&E–stained sections.
No significant difference in heart length. (C) Representative images of 18-mo heart tissues stained with Masson’s Trichrome. Scale bar = 200 μm. (D) Quantitation of
fibrosis from Masson’s Trichrome–stained sections. n = 5 mouse hearts per group. Five sections per individual, three areas per section. Kruskal–Wallis test for grouped
data, mean ± SD. (E, F) Immunofluorescent staining for wheat germ agglutinin (red) and DAPI (blue) in longitudinal (E) and transverse (F) sections of cardiomyocytes in
heart tissues. Scale bar = 50 μm. (E, F, G, H) Quantitation of cardiomyocyte length (G) and cross-sectional area (H) from WGA staining in (E, F). Kruskal–-Wallis test for
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genes using Ingenuity Pathway Analysis. “Antigen presentation
pathway” was the only pathway significantly up-regulated in the B6N
compared with the B6J (Table S2), and there were no significantly
enriched pathways between the B6N and B6J-Nnt, nor the B6J and
B6J-Nnt (data not shown). We subsequently filtered the expression
data for genes which were regulated in a strain-dependent manner
(87 genes, Fig 3A and Table S3) and in an NNT-dependent manner (64
genes, Fig 3B and Table S4) (q < 0.05). GeneOntology (GO) enrichment
analysis revealed an overrepresentation of genes associated with
muscle contraction in the strain-dependent analysis (Fig 3C) and
numerous pathways associated with immune responses in NNT-
dependent genes (Fig 3D).
Within the cluster of genes associated withmuscle contraction, we
found many genes typically associated with cardiac remodelling up-
regulated in the B6N:myosin heavy chain 7 (Myh7), myosin light chain
4 (Myl4), myosin light chain 7 (Myl7), troponin T1, skeletal type (Tnnt1),
natriuretic peptide precursor A (Nppa), and natriuretic peptide
precursor B (Nppb). These genes are markers of hypertrophy and are
often altered in the heart in disease states as the tissue reverts to a
more “foetal” expression pattern 24, 25, 26. The expression levels of
these genes and their associated binding partners were assessed in
the three age-groups by RT-qPCR (Fig 4). Some of the differentially
expressed cardiac genes were significantly altered on RT-qPCR (Myh7
and Tnnt1), whereas the others showed a strain-dependent trend. No
sequence variants were found in these genes to explain their dif-
ferential expressions (Table S5).
Variant calling pipeline highlights Mylk3 as the likely causative
gene
It is unclear whether the gene expression changes we see are drivers
of or responses to the DCM phenotype. Almost all genes within the
cardiac remodelling cluster have been linked to cardiomyopathies,
not limited to the dilated form (27). We mined the RNAseq data for
genetic variants between the B6N and B6J, seeking variants which
might explain the differential gene expression patterns or be causal
of the phenotype. Compared with the Mus musculus reference ge-
nome (B6J), 43 variants amongst the B6N and B6J substrains were
identified, 38 in the B6N and 5 in the B6J, potentially affecting 63
genes (Table S5). A variant inMylk3, Chr8:85365179A>T, c-5T>A, SNP ID
rs245783224, was considered a good candidate because it is almost
exclusively expressed in the heart, with ablation resulting in cardiac
dysfunction, which is modest in the germ line knockout (28, 29, 30). In
humans, it is highly expressed in heart and ~10-fold lower in skeletal
muscle, with two recent articles showing an association of variants in
MYLK3 with DCM (31, 32).
Point mutation in Mylk3 abolishes protein expression in B6Nmice
We confirmed this mutation was present in B6N and absent in B6J
mice by Sanger sequencing (Fig 5A) and that this had no effect on
mRNA expression (Fig 5B). Of the 36 inbredmouse strains sequenced
by the Sanger Mouse Genomes Project (33), only the C57BL/6NJ
mouse has the variant. The mutation introduces a putative trans-
lation initiation site (TIS), 5-bp upstream of the canonical TIS. We
used a series of Kozak signature prediction software to assess
whether the new TIS created by the mutation would be a better
match for translation initiation than the canonical TIS (Fig 5C) (34, 35,
36). TIS miner and NetStart 1.0 predicted the variant weakens the
canonical TIS and PreTIS predicted the new ATG to form an alter-
native TIS with a very high confidence score (0.93) (37). The predicted
protein product from this novel TIS would be out of frame and result
in an altered protein with a molecular weight of 3.2 kD. In keeping
with this, MYLK3 protein expression in the B6N mice was absent by
Western blot (Fig 5D). It is important to note MYLK3 expression was
absent at all three ages, showing the “genotype” of these mice with
respect toMYLK3 was consistent across all groups (Fig S5C and D). We
also performed immunohistochemistry (IHC) on formalin-fixed
paraffin-embedded samples (Fig S5A and B), finding no MYLK3 ex-
pression in the C57BL/6N mice. Intriguingly, we found a gradient of
staining in the C57BL/6J mice, with high staining in the papillary
muscles and at themidline of the tissue and less in the endocardium
and at the base and apex. This was surprising, as it is in stark contrast
to the previously reported phospho-MYL2 gradient (19).
To verify the deleterious effect of this variant on protein translation,
a luciferase reporter assay was performed using vectors containing
either the wild-type (B6J) or variant (B6N) 59 UTRs of Mylk3 transcript
variant 1 (NM_175441.5), immediately upstream of the luciferase start
codon. Luciferase signal was normalised by co-transfecting with a GFP
vector and normalising luminescence to fluorescence (Fig 6A). Lu-
ciferase activity was significantly lower in HEK293T cells transfected
with the “B6N-59UTR-Mylk3-Luc” vector than those transfected with
“B6J-59UTR-Mylk3-Luc,” indicating the mutation is sufficient to abro-
gate protein translation (Fig 6B). This was confirmed by expressing
MYLK3 constructs with the respective 59UTRs under a T7 promoter in a
cell-free protein expression system (Promega). The B6J-59UTR-Mylk3-
Luc construct produced a protein at ~86 kD, whereas B6N-59UTR-
Mylk3-Luc showed negligible expression (Fig 6C) and no other protein
was detected. This ~86-kD protein was confirmed to be MYLK3 by
Western blotting (Fig 6D).
We analysed the other three myosin light chain kinase genes,
suspecting one of these may compensate for the absence of MYLK3
in the B6Nmouse. RNAseq data revealedMylk andMylk2 expression
levels were very low in the heart; however, Mylk4 expression level
was similar to Mylk3. Interestingly, Mylk4 expression was higher in
the B6N mice and was identified as a strain-dependent gene by
RNAseq (Table S2). MYLK4 could phosphorylate key targets in the
absence of MYLK3 in the B6N, and this may allow the mice to survive
to adulthood. RT-qPCR revealed Mylk4 was ~1.8-fold higher in the
B6N group at both 3 and 12 mo; however, there was no difference in
protein expression and is, therefore, unlikely to be able to com-
pensate for loss of MYLK3 (data not shown).
grouped data, n = 5, mean ± SD. (I) Immunofluorescence staining for WGA (red), MYL2 (green), and DAPI (blue). Scale bar = 50 μm. (J) Immunofluorescence staining for
WGA (red), alpha-actinin (ACTN1) (green), and DAPI (blue). (I, J, K, L)Quantification of sarcomere length and thickness from images in (I) and (J) using MyofibrilJ. n = 5 mouse
hearts per group. Five sections per individual, three areas per section. Kruskal–Wallis test for grouped data, mean ± SD. (M)Western blot for ACTN1, TNNT2, MYL2, GAPDH,
and NNT in 18-mo heart lysates, n = 3 mice per group. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
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Discussion
Since the discovery of the unique Nnt mutations in B6J mice, many
groups have used this mouse in conjunction with the B6N to study
the role of Nnt, as one might with a traditional knockout and
corresponding wild-type model (13, 38, 39, 40, 41, 42 43). In contrast
to previous studies linking Nnt to cardiac function (12,13,14,16), we
show that Nnt expression levels do not correlate with the DCM
phenotype, although a number of gene expression profiles tracked
with Nnt status in our mouse models (Fig 3B). Instead, we identify a
mutation in Mylk3 in B6N mice that abolishes protein expression
and likely causes DCM, whereas MYLK3-replete B6J mice are un-
affected. Interestingly, the same Mylk3 variant (g.chr8:85365179A>T;
c.-5T>A) was previously described and, although that study found
no evidence of DCM at an early time point (16 wk), it did show the
B6N heart papillary muscles contracted with less force than those
from B6J hearts (44).
Here, we show B6N cardiomyocytes are “stretched,” reflected by
a thinning of the sarcomeres within each cell but found no difference
in individual sarcomere length. The latter finding is particularly in-
teresting, as onemight expect volume overload to stretch themuscle
fibres and increase the sarcomere length. Increases in sarcomere
Figure 3. RNAseq reveals strain-dependent and NNT-dependent genes.
Differentially expressed genes generated by CuffDiff TopHat pipeline, clustered according to the expression profile across samples. Values for each cell are calculated
as the log2[x + 1], where x is the counts for that gene. Each subsequent value for a gene is then subtracted from the average of all the values for that gene. These values are
then used to generate the heat map. Mouse group indicated at the base of each column. (A)Heat map of gene list segregated by strain. (B)Heat map of gene list segregated
by NNT status. (A, C) Gene Ontology list generated by Panther open access software from gene list in (A). (B, D) Gene Ontology list generated by Panther open access
software from gene list in (B).
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Figure 4. RT-qPCR analysis of key cardiac genes.
Collated RT-qPCR data. All RT-qPCR expression values generated by ΔΔCT method. Actc1, actin, alpha, cardiac muscle 1; Myh6, myosin heavy chain 6; Myh7, myosin heavy
chain 7; Myl2, myosin light chain 2; Myl3, myosin light chain 3; Myl4, myosin light chain 4; Myl7, myosin light chain 7; Nppa, natriuretic peptide precursor A; Nppb, natriuretic
peptide precursor B; Tnnt1, troponin T1, skeletal type; Tnnt2, troponin T2, cardiac type. RT-qPCR expression of key cardiac genes. Kruskal–Wallis test at each time point, n = 4,
mean ± SD. # symbol indicates one substrain differs significantly from the other two at that time point with a P-value less than 0.05.
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length enhance the calcium sensitivity of the fibres and increase
contractility (45). The lack of significant difference in sarcomere
length may be due to the comparatively small difference in car-
diomyocyte length. It is unclear what the effect of sarcomere nar-
rowing may be on contractility. It may increase the frequency of actin
and myosin crossbridge formation; however, the evidence for this is
unclear (46, 47).
Mylk3 is a very plausible candidate for the genesis of the DCM
seen in B6N mice. A previous study generated Mylk3−/− mice and
showed they develop a similar phenotype of dilated ventricles, re-
duced fractional shortening, and reduced ejection fraction, whereas
their phenotype is similarly nonlethal (28). As the cardiac isoform of
the family of myosin light chain kinases, MYLK3 phosphorylates MYL2
and potentially autophosphorylates itself (44, 48). MYLK3 expression
is also important for sarcomere assembly. Knockdown of MYLK3
impaired sarcomere assembly in cultured cells and in zebra fish (49).
Conditional adult-onset Mylk3 knockout mice have drastically re-
duced MYL2 phosphorylation which precedes heart failure (29, 30),
whereas germ line ablation causes mice to develop DCM in adult-
hood, and perinatal ablation produces an intermediate phenotype
(28). A previous report demonstrated B6N mice have reduced rather
than absentMYL2 phosphorylation (44) because of absence ofMYLK3,
Figure 5. SNP in Mylk3 abolishes protein expression
in C57BL/6N hearts.
(A) Representative chromatogram of Sanger
sequencing of Mylk3 in DNA isolated from 3-mo heart
samples of each group. Blue box indicates SNP and A
of alternate TIS in B6N and green box indicates the
canonical translation initiation site. (B) RT-qPCR
analysis of Mylk3 expression. One-way ANOVA at
each time point; n = 5, mean ± SD. (C) Kozak signature
analysis of translation initiation site in B6J (upper pane)
and B6N (lower pane) showing the alternate TIS for
the B6N variant. (D)Western blot staining of GAPDH and
MYLK3 in 3-mo heart tissue lysates.
Figure 6. 59UTR MYLK3 mutation in C57BL/6N is sufficient to abrogate protein expression.
(A) Luminescence (upper panel) and fluorescence (lower panel) signal in cells transfected with a combination of empty vector, GFP, and luciferase vectors signified by
the table. Representative experiment from three experimental repeats with six technical replicates. (B) Normalised luminescence. One-way ANOVA Brown–Forsythe and
Welch test; n = 3, mean ± SD. (C) Coupled transcription–translation expression of genes under control of T7 promoter: Sample in lane 1 contains no template DNA; lane 2
contains a luciferase control vector; lane 3 contains a pcDNA3.1(+) vector expressing MYLK3 with the 59UTR from C57BL/6J mice; lane 4 contains a pcDNA3.1(+) vector
expressing MYLK3 with the 59UTR from C57BL/6Nmice. Proteins detected by chemiluminescent substrate. (D) Samples as above, detected by blotting with MYLK3. (C, D) are
representative of three repeats.
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but it has been postulated that another myosin light chain kinase
family member could be maintaining the residual phosphorylation
seen (50).
Phosphorylation of MYL2 is important for the assembly of actin
fibres, and overexpression of MYLK3 increases the speed of the
contractions and relaxations of a spontaneously beating cardiac cell
culture model (19, 48). MYL2-knockout mice are embryonic lethal (51),
yet MYL2 phosphomutants (S14A and S15A) survive to adulthood,
develop DCM and, although more than half survive beyond 12 mo, die
at a significantly quicker rate (52). The disparity in survival between
these different mutants and the germ line versus adult-onset MYLK3
knockouts is worth remarking. Given the lethality of conditional adult
MYLK3 knockouts, it has been suggested that the lack ofMYLK3 in germ
line knockouts during development allows the heart to adapt,
whereas this ability is lost when the knockout is induced in adulthood,
as thesemice develop heart failure and die (28, 29, 30). Intriguingly, we
found up-regulation of Mylk4 expression, present at relatively high
levels in the heart, but this up-regulation was absent at the protein
level. It is likely another unidentified protein is compensating for the
loss of MYLK3 during development, facilitating survival and limiting
disease progression. Discovering the identity of this kinase will be
important to future work into the role and of MYLK3, in both the
broader context of its activity and for the C57BL/6N mouse.
The lack of MYLK3 may also explain the differential responses to
stresses such as transverse aortic constriction (TAC) and angio-
tensin II treatment observed in other studies comparing C57BL/6
mouse substrains (15, 17). The B6N substrains had dilated ventricles,
thinnermuscle walls, and increased expression of foetal geneNppb
compared with a B6J substrain after TAC (17) and showed increased
fibrosis and foetal gene expression in response to chronic an-
giotensin II treatment (15). Interestingly, B6N mice die at a far
greater rate than B6J mice after TAC (17). This mimics the increased
mortality in Mylk3−/− mice compared with WT littermates after TAC
(28). We believe the increased mortality in B6N mice is due to the
Mylk3 mutation present in this substrain.
In our RNAseq data, we find B6N hearts express four times more
Myh7 than hearts from the two B6J substrains. Myh7 is one of two
main cardiac myosin heavy chain isoforms, the other being myosin
heavy chain 6 (Myh6) (53). In humans, MYH7 is predominant in the
ventricles, whereas MYH6 is predominant in atria (54, 55). In mice,
this pattern is observed only during embryogenesis, and then MYH6
is the main isoform across the whole heart (56). Although believed
to have arisen from a duplication event, the two isoforms have
distinct sequences and activities as myosin heavy chain proteins:
MYH6 is a “fast-twitch” cardiac isoform, with faster binding kinetics
and contraction speed than MYH7 (24). Isolated papillary muscles
from B6N mice contract more slowly and with less force and relax
slower than the equivalent muscle isolates from B6J mice.
However, it is equally possible that the increase in Myh7 in B6N
reflects a stress adaptation of the tissue due to the dilation,
particularly as the RNAseq was performed on 18-mo heart tissues.
Under conditions of stress, transcription of foetal genes such as
Myh7 are often increased and this is thought to be due to a de-
repression of their expression by microRNAs (25, 26, 57) The picture
is not quite so clear in our case, as the levels of other foetal genes,
particularly Nppa and Nppb, are higher in the B6J substrains. This
may reflect a more complicated regulation by distinct microRNAs,
but we believe the difference in Myh7 expression is a response to
the dilation of the ventricles, rather than its genesis.
The C57BL/6 strain is the most widely used laboratory strain,
initially made popular for its strong breeding characteristics; the
B6J substrain, originating in The Jackson Laboratory, is by far the
most widely used substrain, accounting for 90% of all published
references to the C57BL/6 strain. However, over the past decade,
international mouse knockout initiatives, the IMPC, European
Conditional Mouse Mutagenesis (EUCOMM), and the National In-
stitutes of Health Knockout Mouse (KOMP) have moved to the
C57BL/6N as a background strain because of greater ES cell effi-
ciency for homologous recombination (58, 59).
It is becoming increasingly clear that these two closely related
substrains have many more genetic/phenotypic differences than is
widely appreciated. Worryingly, one review found that in the journal
Diabetes, 63% of all published articles between 2010 and 2014 that
used a variant of the C57BL/6 strain andmade nomention of the exact
substrain used (6), instead simply stating C57BL/6micewere used. This
appears to be true with other mouse strains, as the authors found
58.5% of all methods sections did not report the exact substrain with
sufficient completeness. Aided by next-generation sequencing
approaches, there are now sizeable databases documenting the
many genetic differences between mouse substrains, including
those involving the B6J and B6N (23, 33, 60, 61, 62). These produce
remarkably different phenotypes regarding weight, blood pressure,
bone density, blood glucose, and cardiovascular traits (3, 17, 23, 63,
64, 65, 66, 67, 68). In this regard, using the partly compromised B6N
model, phenotypic effects may be more apparent and may help us
unveil new important cardiac genes, and hence new therapies.
However, caution must be advised, as researchers may want to
avoid labelling effector genes as “causative” of CM or “essential” for
cardiac function when made on the 6N background.
Conclusions
We have described a Mylk3 mutation that is probably responsible
for a modest CM in the C57BL/6N substrain and demonstrated that
NNT ablation in the C57BL/6J mouse does not, by itself, cause a
cardiac phenotype. TheMylk3mutation is absent in all other mouse
substrains sequenced in the Mouse Genomes Project including the
closely related C57BL/6J mouse. However, many other genomic
variants exist between substrains, the consequences of which are
only gradually being uncovered (61, 69, 70). We clearly demonstrate
how a single gene defect can cause susceptibility to a particular
phenotype in a mouse substrain, in this case CM in the B6N. Hence,
this study accentuates the importance, in a wider setting, of
knowing the genetic defects in your mouse substrain and highlights
the value of selecting your mouse background with care.
Materials and Methods
Animal husbandry
All mice were bred, housed, and culled at Medical Research Council
Harwell, and therefore, the husbandry was identical for all three
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substrains. Only male mice were used in this study. Mice were kept
and studied in accordance with the UK Home Office legislation and
local ethical guidelines issued by the Medical Research Council
(Responsibility in the Use of Animals for Medical Research, July 1993;
Home Office license 30/3146). Mice were kept under controlled light
(light 7 AM–7 PM, dark 7 PM–7 AM), temperature (21°C ± 2°C), and hu-
midity (55% ± 10%) conditions. They had free access to water (9–13
ppm chlorine) and were fed ad libitum on a commercial diet (SDS
Rat and Mouse No. 3 Breeding diet, RM3, 3.6 kcal/g). The mouse
strains used were C57BL/6NTac originally from Taconic (Taconic
Biosciences), C57BL/6J distributed by Charles River (Charles River
UK), and C57BL/6J mice carrying a bacterial artificial chromosome
transgene to restore murine Nnt (officially C57BL/6J-Tg(RP22-
455H18)TG1Rdc/H). All mice used were no more than 10 genera-
tions of mating removed from restock.
Echocardiography
A week before culling, the cardiac phenotype of each cohort of
mice was assessed using echocardiography. The mice were
anaesthetised under 4% isoflurane, then maintained at 1.5–2% for
the duration. For the echocardiogram, the left ventricle of the heart
was imaged and analysed using the Vevo770 (FUJIFILM Visual-
Sonics) according to the IMPC phenotyping protocol. More details
of this procedure can be found on www.mousephenotype.org/
impress.
Clinical chemistry
Free-fed mice were terminally anaesthetised at 3, 12, or 18 mo with
isoflurane, and blood was collected from the retro-orbital sinus
using uncoated glass capillary tubes (Cat. no. 612-2439; VWR) into
either lithium heparin or EDTA-coated paediatric tubes (Cat. no.
078028 & 077030; Kabe Labortechnik). Lithium heparin samples
were kept on wet ice and centrifuged within 1 h of collection for 10
min at 5,000g in a refrigerated centrifuge set to 8°C. Plasma
samples were analysed for sodium, potassium, chloride, glucose,
triglycerides, free fatty acids, and total-, high-density lipoprotein–,
and low-density lipoprotein cholesterol on board a Beckman
Coulter AU680 clinical chemistry analyser using reagents and




After bleeding, mice were dissected under a laminar flow tissue
culture hood. Tissues were removed and immediately snap frozen
in liquid nitrogen or immersed in 4% PFA. All animals were culled
between 1,000 and 1,130 h. All animal protocols in this study were
approved by the United Kingdom Home Office.
Heart weights and tibia lengths
Frozen isolated heart tissues were weighed to an accuracy of 0.1 mg.
Tibia lengths of C57BL/6N and C57BL/6J mice were measured using
X-ray at 13 wk.
Genotyping
Genomic DNA was extracted from the mouse tail tissue using a
DNeasy tissue kit (QIAGEN). Mice were genotyped for Nnt status
using previously published primers (3).
Tissue extraction for RNA-Seq
Five 18-mo-old mice of the three different substrains were used per
group. RNA was isolated from intact hearts using the RNeasy Mini Kit
(QIAGEN). RNA samples were processed by INVIEW Transcriptome
Discover service (GATC Biotech) and resultant FASTQ files processed
as follows.
Quality filtering
We used Trim Galore (http://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/), a wrapper tool around Cutadapt (71) and
FastQC (72) (https://www.bioinformatics.babraham.ac.uk/projects/
fastqc/), to filter reads with quality Phred score cutoff less than 20
and trim Illumina TruSeq adapters in FASTQ files.
Differential gene expression
We used TopHat (73) to align quality filtered reads to the M. mus-
culus reference genome (GRCm38) (74), discarding final read
alignments having more than two mismatches. We obtained 89.0%,
88.8%, and 87.8% concordant pair alignment rate for heart knockout,
wild-type, and rescue, respectively. Finally, we used CuffDiff (75) to
calculate expression in samples and test the statistical significance
of each observed change in expression between them, using a
q-value of <0.05 as the threshold for significance.
RNAseq variant calling
We followed GATK pipeline for variant calling in RNAseq (https://
software.broadinstitute.org/gatk/documentation/article.php?
id=3891). We used the STAR 2-pass method from STAR aligner (76,
77) to align the quality filtered reads to the reference genome
downloaded from ftp://ftp-mouse.sanger.ac.uk/ref/GRCm38_68.fa.
Then, we used Picard to add read groups, sort, and mark du-
plicates (https://broadinstitute.github.io/picard/). We used
SplitNCigarReads from GATK (78, 79, 80), to split reads into exon
segments and hard-clip any sequences overhanging into the
intronic regions. We then applied indel realignment and base
recalibration from GATK. Finally, we used HaplotypeCaller (81
Preprint) for variant calling. Variants were validated by visual-
ising alignments in the Integrative Genomics Viewer browser (82)
from the Broad Institute.
Compared with the M. musculus reference genome (6J), 79 var-
iants amongst the B6N and B6J substrains were identified, po-
tentially affecting 98 genes. Visual inspection of these variants in
Integrative Genomics Viewer browser allowed us to eliminate 35
variants on the basis (mostly) of misalignment of short-read
sequencing in repetitive regions, leaving 43 variants which
differed from the B6J reference sequence with the potential to
affect 63 genes. 38 of these varied in the B6N substrain with the
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remaining five in B6J, all were biallelic with the exception of one
variant, in cue domain-containing protein 1 (Cuedc1) which
was monoallelic in B6J. This apparent heterozygosity is likely
due to alignment of short sequencing reads to more than one
locus.
Amongst the biallelic variants, the one inMylk3, Chr8:85365179A>T,
c-5T>A, SNP ID rs245783224, was considered a likely candidate be-
cause MYLK3 is almost exclusively expressed in the heart, with ab-
lation resulting in cardiac dysfunction, which is modest in the germ
line knockout (28, 29, 30). In humans, it is highly expressed in heart
with two recent articles showing an association of variants in MYLK3
with DCM (31, 32).
GO-term analysis
Gene lists were analysed using Panther Gene List analysis and
a statistical overrepresentation test. GO terms for pathways
overrepresented in these lists were generated by the software
(83, 84).
RT-qPCR
We isolated RNA from whole tissues using the TRIzol method,
followed by a sodium acetate–ethanol cleanup to remove salt
contamination (85, 86). Genomic DNA was removed by compre-
hensive DNAse treatment and RNA was converted to cDNA (Invi-
trogen). cDNA was then used to assess RNA expression by qPCR,
calculated by the ΔΔCT method (Kapa Biosystems). Amplicons
obtained from manually designed primers were confirmed by
Sanger sequencing (GATC).
Primers were manually designed using PrimerQuest Tool (In-
tegrated DNA Technologies) and synthesised by Sigma-Aldrich
(Merck). Primer sequences are listed in the following table.
Western blotting
Protein lysates were obtained by homogenising and lysing tissues in
radio immunoprecipitation assay buffer for 2 h at 4°C. The lysates were
sonicated at 20 kHz twice for 10 s, then centrifuged at 16,000g for 15
min, and the resultant supernatants were normalised for total protein
concentration with a bicinchoninic acid assay. Protein lysates were
added to an equal volume of Laemmli buffer. Lysates were heated
at 95°C for 5 min and then loaded into 4–12% SDS gels. Immu-
noblots for NNT were performed with unheated samples. Proteins
were then separated based on size using electrophoresis and
transferred to a nitrocellulose membrane (Sigma-Aldrich) by semi-
dry transfer blot (Bio-Rad) at 15 V for 1 h. Membranes were probed
with a target antibody and GAPDH. Antibodies used are as follows:
mouse anti-NNT (1:1,000, HPA004829; Sigma-Aldrich), mouse anti-
TNNT2 (1:2,000, Cat. no. ab8295, RRID:AB_306445; Abcam), mouse
anti-Sarcomeric Alpha Actinin (1:2,000, Cat. no. ab9465, RRID:
AB_307264; Abcam), rabbit anti-MYLK3 (1:1,000, Cat. no. AP7965a,
RRID:AB_2266783; Abgent), rabbit anti-GADPH (1:2,000, Cat. no.
ab9485, RRID:AB_307275; Abcam), and rabbit anti-MYL2 (1:5,000, Cat.
no. ab79935, RRID:AB_1952220; Abcam).
H&E
Freshly isolated hearts were immersed in 4% PFA on ice overnight.
Tissues were then dehydrated and embedded in paraffin wax. We
cut 7-μm sagittal sections through the tissues, making note of serial
section number. Sections obtained at similar planes were then
used for haematoxylin and eosin staining using a Leica Autostainer
(87). Briefly, tissue sections were washed in distilled water followed
by staining with Gill’s 3 Hematoxylin to stain nuclei and Eosin Y to
counterstain cytoplasmic regions. We imaged stained sections
using a Panoramic 250 (3D Histech) slide scanner with CaseViewer
software.
Masson’s Trichrome
We stained paraffin-embedded heart sections as described in refer-
ence 88. Briefly, we fixed sections in Bouin’s solution for 1 h followed
by intense washing. We then stained fixed sections with Weigert’s
haematoxylin (nuclei), Biebrich scarlet-acid fuchsin solution (plasma),
and Aniline Blue (collagen). We imaged stained sections using a
Panoramic 250 (3D Histech) slide scanner with Panoramic Viewer
software. We assessed fibrosis in these images in ImageJ using a
colour threshold–detecting blue staining, determined by a pre-
nominated window for colour hue, and passing a fixed intensity
threshold.
Immunohistochemistry
We used two detection methods for protein localisation, one using
chromogenic diaminobenzidine oxidation assays and the other
epifluorescence coupled with conjugate fluorescent dyes. Chro-
mogenic diaminobenzidine staining of MYLK3 was performed by a
Ventana automated staining station using the OmniMap Rabbit HRP
(Roche). We imaged stained sections using a Panoramic 250 (3D
Histech) slide scanner with CaseViewer software.
Individual gene names with corresponding forward and reverse primer
sequences for RT-qPCR. Sequences are all expressed 59 –> 39
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For epifluorescence staining, paraffin tissue sections were cleared
and dehydrated followed by boiling in a citrate buffer to expose
protein epitopes. Specimens were then blocked in a BSA–serum
mixture, followed by primary antibody incubation overnight. Samples
were washed and incubated with secondary antibody, washed and
finally mounted in an aqueous mountant. For immunofluorescent
sections, tissues were counterstained with DAPI and wheat germ
agglutinin Alexa Fluor 555 conjugate (Thermo Fisher Scientific) before
background removal with TrueView Autofluorescence quenching kit
(Vector Labs) followed by mounting in VectaShield mounting me-
dium. Fluorescent slides were imaged on a Zeiss LSM 880 with
Airyscan and quantified by MyofibrilJ package in ImageJ. DAB-
stained slides were imaged using a Panoramic 250 (3D Histech)
slide scanner with CaseViewer software. For sarcomeric morpho-
metrics, longitudinal and transverse heart sections were used to
measure the long axis (longitudinal sections) and CSA (transverse
section) of individual cardiomyocytes delineated by WGA, alpha-
actinin (1:5,000, Cat. no. ab9465, RRID:AB_307264; Abcam), and MYL2
(1:1,000, Cat. no. ab79935, RRID:AB_1952220; Abcam) staining. Con-
focal microscopy was performedwith an LSM880Microscope (Zeiss)
on a 63× objective.
Luciferase assay
The 59 UTR of Mylk3 transcript variant 1 from B6N or B6J mice was
cloned immediately upstream of the luciferase ORF in PGL3 (Promega)
by Gibson cloning (89) from a gBlock (Integrated DNA Technologies) to
create the reporter constructs “B6N-59UTR-Mylk3-Luc” and “B6J-59UTR-
Mylk3-Luc.” A CMV promoter and enhancer was also substituted for the
SV40 promoter to increase expression. All constructs were verified by
sequencing. 50 ng of reporter vector or control vector (pcDNA3.1(+)) was
co-transfected with 50 ng pcDNA3.1(+) expressing GFP using lipofect-
amine 3000 reagent (Invitrogen). 24 h post-transfection the cells were
incubatedwith a luciferase recordingmediumcontainingD-luciferin at
0.45 mg/ml and bioluminescence was recorded in an integrated
ClarioStar microplate reader (BMG Labtech) for 30 min. The plate
was washed three times in PBS, and GFP fluorescence was recorded.
Luciferase activity was normalised to fluorescence to control for
transfection efficiency. The experiment was performed three times
with six technical repeats per experiment.
Coupled transcription/translation assay
A MYLK3 ORF clone generated by GenScript (Clone ID: OMu23765) in
the pcDNA3.1(+) vector was used as the backbone for subsequent
59UTR cloning. 59 UTR of B6N and B6J MYLK3 was cloned immediately
upstream of the canonical ATG and immediately downstream of the
T7 promoter by Gibson Assembly (89) and confirmed by Sanger
sequencing. 1 μg of plasmid was added to 40 μl of TnT Quick Master
Mix (Promega) with 1 μl of methionine and 1 μl of Transcend Biotin-
Lysyl-tRNA and incubated at 30°C for 1 h. A negative control reaction
was set up containing no plasmid DNA, and a positive control
containing a luciferase expression vector. The products of each
reaction were separated by SDS–PAGE and then transferred onto a
nitrocellulose membrane. The membrane was blocked in 5% BSA
and incubated with MYLK3 and detected byWestern blot protocol or
with streptavidin–HRP conjugate and incubated for 2 h, followed by
detection with substrate as per the manufacturer’s instructions
(Promega). Membranes were visualised using a Licor Odyssey Fc
and ImageStudio software.
Statistical analysis
Statistical tests are described on a per experiment basis in the
figure legends describing the experiment in question.
Availability of data and materials
The dataset supporting the conclusions of this article is available in
the NCBI Bioproject repository: Bioproject ID PRJNA531833, http://
www.ncbi.nlm.nih.gov/bioproject/531833.
Supplementary Information
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